American biopharmaceutical and research companies are developing nearly 300 vaccines for the prevention and treatment of a variety of diseases, according to a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA). Under review by the Food and Drug Administration or in clinical trials, the vaccines include 170 for infectious diseases, 102 for cancers and eight for neurological disorders. “Vaccines are one of the greatest achievements of biomedical science and public health,” said PhRMA President and CEO John Castellani. “Over the past few decades, vaccinations have helped prevent and in some cases nearly eliminate contagious and deadly diseases affecting children and adults alike.” Vaccines in development include those for pancreatic cancer, HIV, meningococcal disease, Alzheimer’s disease, and malaria. See PhRMA Press Release, April 20, 2012.